PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII) announced today the presentation of data from two studies evaluating the company’s NEUGENE® PLUS therapeutic antisense compounds in the treatment of nonhuman primates (NHP) exposed to the Ebola virus. Results of the studies were presented at the National Institutes of Health’s Filovirus Animal Workshop by Dr. Sina Bavari, principal investigator, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
